| Submission declined on 26 October 2024 by LR.127 (talk). This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Once you save your changes using the "Publish changes" button below, you will be able to resubmit your draft for review by pressing the "Resubmit" button that will appear here. |  |
The Advanced Radioisotope Technology for Health Utility Reactor (ARTHUR) is a state-of-the-art nuclear facility proposed for development in North Wales, aimed at significantly enhancing the UK's capacity to produce vital nuclear medicines. Spearheaded by the Welsh Government, with the support of a detailed outline business case and feasibility study, the project is, as of Summer 2024, under consideration by the UK Government [1]. ARTHUR will focus on producing key isotopes such as Technetium-99m (Tc-99m), the most widely used radioisotope in medical diagnostics, essential for imaging in areas such as cardiology and oncology. They are also a key part of future tailored medicines to simultaneously image and treat cancers: termed theranostics. By securing domestic production of these critical medical isotopes, the reactor will play a pivotal role in strengthening the UK’s healthcare infrastructure and reducing reliance on international suppliers, ultimately ensuring a stable and timely supply of life-saving diagnostic tools.
The project was initiated in 2019, after the cessation of the Wylfa Newydd programme by the Welsh Government. The Trawsfynydd site, currently in decommissioning, was chosen after a siting study, owing to its nuclear history, need for economic uplift, existing nuclear licensed site, and proximity to infrastructure. Following a global nuclear medicine supply chain shortage in the late 2010s-2020s, the project has been developed to deliver medicines to the UK market in the early 2030's, just as other supplies are expected to cease, supporting the NHS recommendation [2].
In the UK, nuclear medicine procedures are a critical component of diagnostic and therapeutic healthcare. As of recent data, it is estimated that approximately 1 million nuclear medicine procedures are carried out annually across the country [3]. This includes a range of diagnostic imaging procedures, such as PET (positron emission tomography) scans and SPECT (single-photon emission computed tomography) scans, as well as therapeutic procedures involving radiopharmaceuticals.
- ^ "Welsh Government unveils major plans for national nuclear medicine laboratory in north Wales | GOV.WALES". www.gov.wales. January 10, 2023. Archived from the original on February 21, 2024. Retrieved September 14, 2024.
- ^ "Response to the ARSAC Report 'A Review of the Supply of Molybdenum-99, the Impact of Recent Shortages and the Implications for Nuclear Medicine Services in the UK'" (PDF).
- ^ Young, Jennifer D.; Jauregui-Osoro, Maite; Wong, Wai-Lup; Cooper, Margaret S.; Cook, Gary; Barrington, Sally F.; Ma, Michelle T.; Blower, Philip J.; Aboagye, Eric O. (December 14, 2021). "An overview of nuclear medicine research in the UK and the landscape for clinical adoption". Nuclear Medicine Communications. 42 (12): 1301–1312. doi:10.1097/MNM.0000000000001461. PMC 8584216. PMID 34284442.